Boston Scientific Corporation $BSX Shares Sold by R Squared Ltd

R Squared Ltd lessened its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 67.6% during the first quarter, HoldingsChannel reports. The firm owned 9,963 shares of the medical equipment provider’s stock after selling 20,754 shares during the quarter. R Squared Ltd’s holdings in Boston Scientific were worth $625,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. FWL Investment Management LLC purchased a new position in Boston Scientific during the second quarter worth approximately $26,000. Swiss RE Ltd. acquired a new position in shares of Boston Scientific during the fourth quarter worth about $26,000. Garton & Associates Financial Advisors LLC purchased a new position in Boston Scientific in the 4th quarter worth approximately $26,000. Bangor Savings Bank boosted its stake in shares of Boston Scientific by 94.7% in the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 142 shares during the period. Finally, Board of the Pension Protection Fund acquired a new position in Boston Scientific in the 4th quarter worth $29,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Price Performance

BSX stock traded up $0.69 during trading hours on Tuesday, hitting $45.29. 4,761,435 shares of the stock traded hands, compared to its average volume of 18,170,854. The stock has a 50-day simple moving average of $50.99 and a 200 day simple moving average of $69.27. The company has a market cap of $67.31 billion, a P/E ratio of 18.94, a P/E/G ratio of 0.86 and a beta of 0.58. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a one year low of $42.25 and a one year high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same period in the prior year, the business earned $0.75 earnings per share. The business’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts forecast that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has approved a share repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Insiders Place Their Bets

In other Boston Scientific news, Director Cheryl Pegus bought 1,770 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the transaction, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Habiger acquired 2,250 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were acquired at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the transaction, the director directly owned 13,878 shares in the company, valued at approximately $776,057.76. This trade represents a 19.35% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have purchased 9,800 shares of company stock worth $554,012. Company insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on BSX. Robert W. Baird set a $70.00 price objective on shares of Boston Scientific in a research report on Thursday, May 28th. Weiss Ratings cut Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Stifel Nicolaus reduced their price objective on shares of Boston Scientific from $75.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, June 25th. Citigroup reduced their target price on Boston Scientific from $87.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, May 28th. Finally, Evercore set a $65.00 price target on shares of Boston Scientific in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.12.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.